Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Synsight
Deal Size : Undisclosed
Deal Type : Acquisition
Iktos Acquires Synsight for Protein and RNA-Protein Drug Discovery
Details : Iktos acquires Synsight, a life sciences technology specializing in protein-protein and RNA-protein interactions-targeted drug discovery in many diseases such as cancer and neurodegenerative diseases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 08, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Synsight
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Italfarmaco S.p.A
Deal Size : Undisclosed
Deal Type : Collaboration
Italfarmaco Partners with Iktos to Speed Drug Discovery with AI
Details : Italfarmaco collaborates with Iktos to develop next-generation, small molecule HDAC inhibitors for various non-oncological diseases, including diseases affecting the central nervous system.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Italfarmaco S.p.A
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Curreio
Deal Size : Undisclosed
Deal Type : Collaboration
Curreio and Iktos Announce Collaboration in New Drug Discovery
Details : Under the collaboration, Curreio’s state-of-the-art cryo-EM platform in combination with Iktos’ Spaya™ retrosynthesis AI technology, will be used to facilitate the rapid and cost-effective design of novel preclinical drug candidates for an undisclo...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 08, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Curreio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Medicines for Malaria Venture
Deal Size : Undisclosed
Deal Type : Collaboration
Iktos Partners with Medicines for Malaria Venture in Anti-Malarial Drug Discovery
Details : Under the collaboration agreement, Iktos will apply its new ‘DockAI’ technology to expedite the discovery of novel antimalarial drug candidates.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Medicines for Malaria Venture
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Iktos Announces a Collaboration With Ono in Artificial Intelligence for New Drug Design
Details : ONO will acquire exclusive worldwide rights to develop and commercialize small molecule compounds discovered in the collaboration. Iktos will receive research funding plus milestone payments based on achievement of certain milestones.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 30, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?